Visceral leishmaniasis in the BALB/c mouse: sodium stibogluconate treatment during acute and chronic stages of infection: II. Changes in tissue drug distribution
- 1 June 1992
- journal article
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 83 (1-3) , 251-256
- https://doi.org/10.1016/0378-5173(82)90029-1
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Non-Ionic Surfactant Vesicle Formulation of Stibogluconate for Canine LeishmaniasisJournal of Pharmacy and Pharmacology, 1990
- Free and Liposomal Stibogluconate: Tissue Levels and Antiparasitic Activity in the MouseJournal of Pharmacy and Pharmacology, 1990
- Visceral leishmaniasis in the BALB/c mouse: sodium stibogluconate treatment during acute and chronic stages of infectionInternational Journal of Pharmaceutics, 1989
- Visceral leishmaniasis: Resistance to reinfection in the liver following chemotherapy in the BALB/c mouseExperimental Parasitology, 1989
- Visceral Leishmaniasis: Drug Carrier System Characteristics and the Ability to Clear Parasites from the Liver, Spleen and Bone Marrow in Leishmania donovani Infected BALB/c MiceJournal of Pharmacy and Pharmacology, 1989
- The therapeutic effect of sodium stibogluconate in BALB/c mice infected with Leishmania donovani is organ-dependentJournal of Pharmacy and Pharmacology, 1988
- Delivery of liposome-encapsulated drugs to macrophagesPharmacology & Therapeutics, 1983
- Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomesJournal of Antimicrobial Chemotherapy, 1981
- Kala-azar in Zambia: first report of two casesTransactions of the Royal Society of Tropical Medicine and Hygiene, 1976
- Kala-azar in East AfricaTransactions of the Royal Society of Tropical Medicine and Hygiene, 1944